Pediapharm Naproxen Suspension: Formulary list price $0.0949/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0949 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19661 · Verify on the e-Formulary ↗ (DIN 02162431)
Source record
DIN 02162431: Pediapharm Naproxen Suspension
Raw flags: sec3=Y
Item: 280804054; group id 389; item number 0931; lccId None; manufacturer id MPI
Source form: O/L; strength: 25mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.0949; ministry $0.0949
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162431
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19661
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162431
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen · DIN 00522651 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Naproxen · DIN 00522651
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1982-12-31 · brand APO-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 250 MG · company Apotex inc · schedule Prescription
Apo-Naproxen: Formulary list price $0.1068/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1068 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4980 · Verify on the e-Formulary ↗ (DIN 00522651)
Source record
DIN 00522651: Apo-Naproxen
Raw flags: sec3=Y
Item: 280804034; group id 389; item number 0933; lccId None; manufacturer id APX
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.1068; ministry $0.1068
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00522651
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4980
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn · DIN 02162474 · not recorded
Teva-Naproxen · DIN 00565350 · $0.1068
Shortage status: resolved shortage (ended 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00522651
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen · DIN 00565350 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen · DIN 00565350
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 250 MG · company Teva canada limited · schedule Prescription
Teva-Naproxen: Formulary list price $0.1068/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1068 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5036 · Verify on the e-Formulary ↗ (DIN 00565350)
Source record
DIN 00565350: Teva-Naproxen
Raw flags: sec3=Y
Item: 280804034; group id 389; item number 0933; lccId None; manufacturer id TEV
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.1068; ministry $0.1068
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00565350
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5036
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00522651 · $0.1068
Naprosyn · DIN 02162474 · not recorded
Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00565350
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen · DIN 00600806 · 375mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Naproxen · DIN 00600806
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1983-12-31 · brand APO-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 375 MG · company Apotex inc · schedule Prescription
Apo-Naproxen: Formulary list price $0.1458/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1458 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5508 · Verify on the e-Formulary ↗ (DIN 00600806)
Source record
DIN 00600806: Apo-Naproxen
Raw flags: sec3=Y
Item: 280804035; group id 389; item number 0934; lccId None; manufacturer id APX
Source form: Tab; strength: 375mg
Recorded listing: General benefit
Source prices (unrounded): $0.1458; ministry $0.1458
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00600806
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5508
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn · DIN 02162482 · not recorded
Teva-Naproxen · DIN 00627097 · $0.1458
Shortage status: resolved shortage (ended 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00600806
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen · DIN 00627097 · 375mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen · DIN 00627097
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 375 MG · company Teva canada limited · schedule Prescription
Teva-Naproxen: Formulary list price $0.1458/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1458 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5860 · Verify on the e-Formulary ↗ (DIN 00627097)
Source record
DIN 00627097: Teva-Naproxen
Raw flags: sec3=Y
Item: 280804035; group id 389; item number 0934; lccId None; manufacturer id TEV
Source form: Tab; strength: 375mg
Recorded listing: General benefit
Source prices (unrounded): $0.1458; ministry $0.1458
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00627097
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5860
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00600806 · $0.1458
Naprosyn · DIN 02162482 · not recorded
Shortage status: resolved shortage (ended 2026-06-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00627097
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen · DIN 00592277 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Naproxen · DIN 00592277
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1983-12-31 · brand APO-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 500 MG · company Apotex inc · schedule Prescription
Apo-Naproxen: Formulary list price $0.4522/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4522 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5222 · Verify on the e-Formulary ↗ (DIN 00592277)
Source record
DIN 00592277: Apo-Naproxen
Raw flags: sec3=Y
Item: 280804036; group id 389; item number 0935; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.4522; ministry $0.4522
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00592277
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5222
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn · DIN 02162490 · not recorded
Teva-Naproxen · DIN 00589861 · $0.4522
Shortage status: resolved shortage (ended 2026-08-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00592277
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen · DIN 00589861 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen · DIN 00589861
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 500 MG · company Teva canada limited · schedule Prescription
Teva-Naproxen: Formulary list price $0.4522/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4522 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5183 · Verify on the e-Formulary ↗ (DIN 00589861)
Source record
DIN 00589861: Teva-Naproxen
Raw flags: sec3=Y
Item: 280804036; group id 389; item number 0935; lccId None; manufacturer id TEV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.4522; ministry $0.4522
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00589861
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5183
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00592277 · $0.4522
Naprosyn · DIN 02162490 · not recorded
Shortage status: resolved shortage (ended 2026-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00589861
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen EC · DIN 02246699 · 250mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Naproxen EC · DIN 02246699
Manufacturer: Apotex Inc.; listing date 2008-01-15
Health Canada: Marketed since 2003-04-23 · brand APO-NAPROXEN EC TABLETS · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 250 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70894 · Verify on the e-Formulary ↗ (DIN 02246699)
Source record
DIN 02246699: Apo-Naproxen EC
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804100; group id 389; item number 0928; lccId None; manufacturer id APX
Source form: Ent Tab; strength: 250mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.2835; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246699
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70894
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn E · DIN 02162792 · not recorded
Teva-Naproxen EC · DIN 02243312 · not recorded
Shortage status: active shortage (reported 2026-05-26, estimated to end 2026-09-25, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246699
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen EC · DIN 02243312 · 250mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen EC · DIN 02243312
Manufacturer: Teva Canada Limited; listing date 2008-11-04
Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 250 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67215 · Verify on the e-Formulary ↗ (DIN 02243312)
Source record
DIN 02243312: Teva-Naproxen EC
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804100; group id 389; item number 0928; lccId None; manufacturer id TEV
Source form: Ent Tab; strength: 250mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.2835; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243312
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67215
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen EC · DIN 02246699 · not recorded
Naprosyn E · DIN 02162792 · not recorded
Shortage status: resolved shortage (ended 2026-01-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243312
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen EC · DIN 02246700 · 375mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Naproxen EC · DIN 02246700
Manufacturer: Apotex Inc.; listing date 2008-01-15
Health Canada: Marketed since 2003-04-23 · brand APO-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 375 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70895 · Verify on the e-Formulary ↗ (DIN 02246700)
Source record
DIN 02246700: Apo-Naproxen EC
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804101; group id 389; item number 0929; lccId None; manufacturer id APX
Source form: Ent Tab; strength: 375mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3675; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246700
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70895
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn E · DIN 02162415 · not recorded
Teva-Naproxen EC · DIN 02243313 · not recorded
Shortage status: resolved shortage (ended 2022-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246700
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen EC · DIN 02243313 · 375mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen EC · DIN 02243313
Manufacturer: Teva Canada Limited; listing date 2008-11-04
Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 375 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67216 · Verify on the e-Formulary ↗ (DIN 02243313)
Source record
DIN 02243313: Teva-Naproxen EC
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804101; group id 389; item number 0929; lccId None; manufacturer id TEV
Source form: Ent Tab; strength: 375mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3675; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243313
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67216
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen EC · DIN 02246700 · not recorded
Naprosyn E · DIN 02162415 · not recorded
Shortage status: resolved shortage (ended 2026-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243313
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen EC · DIN 02246701 · 500mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Naproxen EC · DIN 02246701
Manufacturer: Apotex Inc.; listing date 2008-01-15
Health Canada: Marketed since 2003-04-23 · brand APO-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 500 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70896 · Verify on the e-Formulary ↗ (DIN 02246701)
Source record
DIN 02246701: Apo-Naproxen EC
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804102; group id 389; item number 0930; lccId None; manufacturer id APX
Source form: Ent Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.6894; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246701
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70896
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn E · DIN 02162423 · not recorded
Teva-Naproxen EC · DIN 02243314 · not recorded
Shortage status: active shortage (reported 2026-07-21, estimated to end 2026-09-25, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246701
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Naprosyn E · DIN 02162423 · 500mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn E · DIN 02162423
Manufacturer: Hoffmann-La Roche Limited; listing date 2008-01-15
Health Canada: Marketed since 2025-04-24 · brand NAPROSYN · ATC M01AE02 NAPROXEN · form Tablet (delayed-release) · route Oral · ingredients NAPROXEN 500 MG · company Searchlight pharma inc · schedule Prescription
Naprosyn E: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19315 · Verify on the e-Formulary ↗ (DIN 02162423)
Source record
DIN 02162423: Naprosyn E
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804102; group id 389; item number 0930; lccId None; manufacturer id HLR
Source form: Ent Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162423
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19315
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen EC · DIN 02246701 · not recorded
Teva-Naproxen EC · DIN 02243314 · not recorded
Shortage status: active shortage (reported 2023-01-30, last updated 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162423
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen EC · DIN 02243314 · 500mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen EC · DIN 02243314
Manufacturer: Teva Canada Limited; listing date 2008-11-04
Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 500 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67217 · Verify on the e-Formulary ↗ (DIN 02243314)
Source record
DIN 02243314: Teva-Naproxen EC
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804102; group id 389; item number 0930; lccId None; manufacturer id TEV
Source form: Ent Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.6894; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243314
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67217
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen EC · DIN 02246701 · not recorded
Naprosyn E · DIN 02162423 · not recorded
Shortage status: resolved shortage (ended 2025-12-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243314
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Naproxen: Formulary list price $0.0781/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0781 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4981 · Verify on the e-Formulary ↗ (DIN 00522678)
Source record
DIN 00522678: Apo-Naproxen
Raw flags: sec3=Y
Item: 280804033; group id 389; item number 0932; lccId None; manufacturer id APX
Source form: Tab; strength: 125mg
Recorded listing: General benefit
Source prices (unrounded): $0.0781; ministry $0.0781
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00522678
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4981
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Naprosyn · DIN 00299413 · not recorded
Shortage status: discontinued (2019-08-05, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00522678
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2019-08-08 — choose a marketed DIN from the same-category list.
Naprosyn · PIN 00299413 · 125mg · tablet
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn · DIN 00299413
Manufacturer: Syntex Inc.; listing date 2001-02-28
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00299413: Naprosyn
Raw flags: notABenefit=Y, sec3=Y
Item: 280804033; group id 389; item number 0932; lccId None; manufacturer id SYN
Source form: Tab; strength: 125mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00299413
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00522678 · $0.0781
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00299413
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Naprosyn E · DIN 02162792 · 250mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.Discontinued 2014-02-05 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn E · DIN 02162792
Manufacturer: Hoffmann-La Roche Limited; listing date 2008-01-15
Health Canada: Cancelled post market since 2014-02-05 · brand NAPROSYN E 250MG TABLETS - ECT · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 250 MG · company Hoffmann-la roche limited · schedule Prescription
Naprosyn E: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19448 · Verify on the e-Formulary ↗ (DIN 02162792)
Source record
DIN 02162792: Naprosyn E
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804100; group id 389; item number 0928; lccId None; manufacturer id HLR
Source form: Ent Tab; strength: 250mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162792
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19448
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen EC · DIN 02246699 · not recorded
Teva-Naproxen EC · DIN 02243312 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162792
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.
Naprosyn · DIN 02162474 · 250mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.Discontinued 2002-01-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn · DIN 02162474
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Health Canada: Cancelled post market since 2002-01-22 · brand NAPROSYN 250MG TABLETS · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 250 MG/TAB · company Hoffmann-la roche limited · schedule Prescription
Naprosyn: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19445 · Verify on the e-Formulary ↗ (DIN 02162474)
Source record
DIN 02162474: Naprosyn
Raw flags: notABenefit=Y, sec3=Y
Item: 280804034; group id 389; item number 0933; lccId None; manufacturer id HLR
Source form: Tab; strength: 250mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162474
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19445
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00522651 · $0.1068
Teva-Naproxen · DIN 00565350 · $0.1068
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162474
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.
Naprosyn E · DIN 02162415 · 375mg · enteric-coated tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.Discontinued 2025-07-25 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn E · DIN 02162415
Manufacturer: Hoffmann-La Roche Limited; listing date 2008-01-15
Health Canada: Cancelled post market since 2025-07-25 · brand NAPROSYN · ATC M01AE02 NAPROXEN · form Tablet (delayed-release) · route Oral · ingredients NAPROXEN 375 MG · company Searchlight pharma inc · schedule Prescription
Naprosyn E: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19316 · Verify on the e-Formulary ↗ (DIN 02162415)
Source record
DIN 02162415: Naprosyn E
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804101; group id 389; item number 0929; lccId None; manufacturer id HLR
Source form: Ent Tab; strength: 375mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162415
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19316
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen EC · DIN 02246700 · not recorded
Teva-Naproxen EC · DIN 02243313 · not recorded
Shortage status: discontinued (2024-07-31, reported by ATNAHS PHARMA UK LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162415
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.
Naprosyn · DIN 02162482 · 375mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.Discontinued 2001-06-27 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn · DIN 02162482
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Health Canada: Cancelled post market since 2001-06-27 · brand NAPROSYN 375MG TABLETS · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 375 MG · company Hoffmann-la roche limited · schedule Prescription
Naprosyn: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19660 · Verify on the e-Formulary ↗ (DIN 02162482)
Source record
DIN 02162482: Naprosyn
Raw flags: notABenefit=Y, sec3=Y
Item: 280804035; group id 389; item number 0934; lccId None; manufacturer id HLR
Source form: Tab; strength: 375mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162482
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19660
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00600806 · $0.1458
Teva-Naproxen · DIN 00627097 · $0.1458
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162482
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.
Naprosyn · DIN 02162490 · 500mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.Discontinued 2002-07-09 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Naprosyn · DIN 02162490
Manufacturer: Hoffmann-La Roche Limited; listing date 2000-04-17
Health Canada: Cancelled post market since 2002-07-09 · brand NAPROSYN 500 MG TABLETS · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 500 MG · company Hoffmann-la roche limited · schedule Prescription
Naprosyn: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19696 · Verify on the e-Formulary ↗ (DIN 02162490)
Source record
DIN 02162490: Naprosyn
Raw flags: notABenefit=Y, sec3=Y
Item: 280804036; group id 389; item number 0935; lccId None; manufacturer id HLR
Source form: Tab; strength: 500mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162490
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19696
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Naproxen · DIN 00592277 · $0.4522
Teva-Naproxen · DIN 00589861 · $0.4522
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162490
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.
NAPROXEN SODIUM
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (M01A, M01AE) — coverage varies; not interchangeable
Flurbiprofen (Ansaid): general benefit, Not a benefit
Ibuprofen (Motrin): general benefit, Not a benefit
Ketoprofen (Ketoprofen): general benefit, Not a benefit
Tiaprofenic acid (Surgam): general benefit, Not a benefit
Oxaprozin (Daypro): not a benefit
Diclofenac (Voltaren): general benefit, Not a benefit
10 more in the class list below
Anaprox · DIN 02162725 · 275mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Anaprox · DIN 02162725
Manufacturer: Hoffmann-La Roche Limited; listing date 2007-12-19
Health Canada: Marketed since 2025-06-26 · brand ANAPROX · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN SODIUM 275 MG · company Searchlight pharma inc · schedule Prescription
Anaprox: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19446 · Verify on the e-Formulary ↗ (DIN 02162725)
Source record
DIN 02162725: Anaprox
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804103; group id 391; item number 0938; lccId None; manufacturer id HLR
Source form: Tab; strength: 275mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162725
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19446
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Apo-Napro-Na · DIN 00784354 · not recorded
Teva-Naproxen Sodium · DIN 00778389 · not recorded
Shortage status: active shortage (reported 2024-07-25, last updated 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162725
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Napro-Na · DIN 00784354 · 275mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Napro-Na · DIN 00784354
Manufacturer: Apotex Inc.; listing date 2007-12-19
Health Canada: Marketed since 1989-12-31 · brand APO-NAPRO-NA · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN SODIUM 275 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10035 · Verify on the e-Formulary ↗ (DIN 00784354)
Source record
DIN 00784354: Apo-Napro-Na
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804103; group id 391; item number 0938; lccId None; manufacturer id APX
Source form: Tab; strength: 275mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3422; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00784354
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10035
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Anaprox · DIN 02162725 · not recorded
Teva-Naproxen Sodium · DIN 00778389 · not recorded
Shortage status: resolved shortage (ended 2022-08-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00784354
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Naproxen Sodium · DIN 00778389 · 275mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Naproxen Sodium · DIN 00778389
Manufacturer: Teva Canada Limited; listing date 2022-08-31
Health Canada: Marketed since 2010-07-20 · brand TEVA-NAPROXEN SODIUM · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN SODIUM 275 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9241 · Verify on the e-Formulary ↗ (DIN 00778389)
Source record
DIN 00778389: Teva-Naproxen Sodium
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 280804103; group id 391; item number 0938; lccId None; manufacturer id TEV
Source form: Tab; strength: 275mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3422; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00778389
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9241
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.Interchangeable products
Anaprox · DIN 02162725 · not recorded
Apo-Napro-Na · DIN 00784354 · not recorded
Shortage status: resolved shortage (ended 2026-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00778389
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL
Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, PIROXICAM, SULINDAC, TIAPROFENIC ACID
28:08:04 Nonsteroidal Anti-Inflammatory Agents
· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04
and 4 more
1 INDICATIONS
APO-NAPROXEN (naproxen) is indicated for:
• The treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and
ankylosing spondylitis.
• The relief of minor aches and pains in muscles, bones and joints, mild to moderate pain
accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary
dysmenorrhea.
Modified release formulations of naproxen (i.e., enteric coated and sustained release) are not
recommended for initial treatment of acute pain because the absorption of naproxen is
delayed.
For patients with an increased risk of developing cardiovascular and/or gastrointestinal
adverse events, other management strategies that do NOT include the use of NSAIDs should
be considered first. See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS.
Use of APO-NAPROXEN should be limited to the lowest effective dose for the shortest
possible duration of treatment in order to minimize the potential risk for cardiovascular or
gastrointestinal adverse events. See 2 CONTRAINDICATIONS and 7 WARNINGS AND
PRECAUTIONS
APO-NAPROXEN, as a NSAID, does NOT treat clinical disease or prevent its progression.
APO-N…
https://pdf.hres.ca/dpd_pm/00071788.PDF
PM date: July 26, 2023
Source product: APO-NAPROXEN; DIN 00522651; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
TEVA-NAPROXEN SODIUM or TEVA-NAPROXEN SODIUM DS (naproxen sodium) is indicated for:
The relief of mild to moderately severe pain, accompanied by inflammation in conditions
such as musculoskeletal trauma and post-dental extraction.
The relief of pain associated with post-partum cramping and dysmenorrhea.
For patients with an increased risk of developing cardiovascular and/or gastrointestinal
adverse events, other management strategies that do NOT include the use of NSAIDs should
be considered first. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS)
Use of TEVA-NAPROXEN SODIUM or TEVA-NAPROXEN SODIUM DS should be limited to the
lowest effective dose for the shortest possible duration of treatment in order to minimize the
potential risk for cardiovascular or gastrointestinal adverse events. (See 2
CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS)
TEVA-NAPROXEN SODIUM or TEVA-NAPROXEN SODIUM DS, as a NSAID, does NOT treat clinical
disease or prevent its progression.
TEVA-NAPROXEN SODIUM and TEVA-NAPROXEN SODIUM DS, as a NSAID, only relieves
symptoms and decreases inflammation for as long as the patient continues to take it.
1.1 …
https://pdf.hres.ca/dpd_pm/00066719.PDF
PM date: July 18, 2022
Source product: TEVA-NAPROXEN SODIUM; DIN 00778389; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
VIMOVO (naproxen/esomeprazole) is indicated for the treatment of the signs and symptoms of
osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to decrease
the risk of developing gastric ulcers in patients at risk for developing non-steroidal anti-
inflammatory drug (NSAID)-associated gastric ulcers.
VIMOVO is not recommended for initial treatment of acute pain because the absorption of
naproxen is delayed (as with other modified release formulations of naproxen).
For patients with an increased risk of developing cardiovascular (CV) and/or gastrointestinal
(GI) adverse events, other management strategies that do NOT include the use of NSAIDs
should be considered first (see 2 CONTRAINDICATIONS and 7 WARNINGS AND
PRECAUTIONS).
Use of VIMOVO should be limited to the lowest effective dose for the shortest possible duration
of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal ad verse
events (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS).
VIMOVO, as a NSAID, does NOT treat clinical disease or prevent its progression.
VIMOVO, as a NSAID, only relieves symptoms and decreases inflammation for …
https://pdf.hres.ca/dpd_pm/00068301.PDF
PM date: Nov 16, 2022
Source product: VIMOVO; DIN 02361701; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Teva-Naproxen · DIN 00565350
Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00565350
Apo-Naproxen EC · DIN 02246699
Shortage status: active shortage (reported 2026-05-26, estimated to end 2026-09-25, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246699
Apo-Naproxen EC · DIN 02246701
Shortage status: active shortage (reported 2026-07-21, estimated to end 2026-09-25, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246701
Naprosyn E · DIN 02162423
Shortage status: active shortage (reported 2023-01-30, last updated 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162423
Naprosyn E · DIN 02162415
Shortage status: discontinued (2024-07-31, reported by ATNAHS PHARMA UK LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162415
Anaprox · DIN 02162725
Shortage status: active shortage (reported 2024-07-25, last updated 2026-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02162725
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Apo-Naproxen EC, Teva-Naproxen EC, Naprosyn E, Naprosyn, Anaprox, Apo-Napro-Na, Teva-Naproxen Sodium: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.